Brief: Metacrine Achieves Full Enrollment For Met642 Phase 2A Trial In Patients With Nash
09/09/2021 14:27
Metacrine, Inc. MTCR.O :
* METACRINE ACHIEVES FULL ENROLLMENT FOR MET642 PHASE 2A
TRIAL IN
PATIENTS WITH NASH
* METACRINE, INC. - TOPLINE MET642 TRIAL RESULTS FROM ALL
PATIENTS
ARE ANTICIPATED IN FIRST HALF OF 2022
* METACRINE, INC. - INTERIM DATA FROM FIRST 60 PATIENTS
EXPECTED
EARLY IN Q4 OF 2021
Source text for Eikon: ID:nGNX7k4bLQ
Further company coverage: MTCR.O
Recent news on Metacrine
See all newsMetacrine Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Metacrine - Filed Certificate Of Dissolution With Secretary Of State Of State Of Delaware To Effect Complete Liquidation And Dissolution Of Company
Brief: Metacrine Inc Common Stock Will Be Delisted From Nasdaq
Brief: Metacrine Inc- On Jan 31, Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Brief: Metacrine CEO Preston Klassen Was Terminated From All Positions